| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7872049 | POHL BOSKAMP | Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate |
Mar, 2029
(5 years from now) | |
Nitrolingual is owned by Pohl Boskamp.
Nitrolingual contains Nitroglycerin.
Nitrolingual has a total of 1 drug patent out of which 0 drug patents have expired.
Nitrolingual was authorised for market use on 31 October, 1985.
Nitrolingual is available in spray, metered;sublingual dosage forms.
Nitrolingual can be used as method of treating angina pectoris.
The generics of Nitrolingual are possible to be released after 12 March, 2029.
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 31 October, 1985
Treatment: Method of treating angina pectoris
Dosage: SPRAY, METERED;SUBLINGUAL
NITROLINGUAL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic